Description: Skye Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is based in San Diego, California
Home Page: skyebioscience.com
11250 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 410 0266
Officers
| Name | Title |
|---|---|
| Mr. Punit S. Dhillon B.A., BA | Exec. Chairman, Pres, CEO & Sec. |
| Ms. Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Mr. Tu Diep M.Sc. | Chief Devel. Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.487 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |